Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Dysplasia 1

Interventions

terameprocol 1methyl 5-aminolevulinate 1fludarabine phosphate 1fludarabine 1aldesleukin 1Respiratory Function Tests 1Prochlorperazine 1Positron-Emission Tomography 1Ondansetron 1O(6)-codeine methyl ether 1Mutagenesis, Insertional 1Meperidine 1Magnetic Resonance Imaging 1Loperamide 1Interleukin-2 1Innovar 1Indomethacin 1Hydroxyzine 1Human Papillomavirus Recombinant Vaccine nonavalent 1Granisetron 1Electrocardiography 1Droperidol 1Doxylamine 1Diphenoxylate 1Diphenhydramine 1Cyclophosphamide 1Codeine 1Cell Count 1Biopsy 1Atropine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Uterine Cervical Dysplasia × Mutagenesis, Insertional × Clear all
NCT05502367 2026-02-19

A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia

Antiva Biosciences

Phase 1/2 Terminated
44 enrolled
Gynecologic

Uterine Cervical Dysplasia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡